Efficacy and safety of pirenzepine in peptic ulcer and in non ulcerous gastroduodenal diseases. A multicentre controlled clinical trial.
D000328:Adult; D001570:Benzodiazepinones / Q000009:adverse effects / Q000627:therapeutic use*; D002229:Carbenoxolone / Q000627:therapeutic use; D002927:Cimetidine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004381:Duodenal Ulcer / Q000188:drug therapy*; D004382:Duodenitis / Q000188:drug therapy*; D005260:Female; D005756:Gastritis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use*; D010890:Pirenzepine; D011377:Proglumide / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D012795:Sialoglycoproteins / Q000627:therapeutic use; D013276:Stomach Ulcer / Q000188:drug therapy*
D001570:Benzodiazepinones; D009025:Morpholines; D010276:Parasympatholytics; D011725:Pyridines; D012795:Sialoglycoproteins; C009354:sulglicotide; D010890:Pirenzepine; D002927:Cimetidine; C012595:trithiozine; D011377:Proglumide; D002229:Carbenoxolone